GYRE THERAPEUTICS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $116.6M | $105.8M | $113.5M | $102.3M | $7.3M |
| Cost of revenue | $5.4M | $3.9M | $4.6M | $4.8M | — |
| Gross profit | — | $101.9M | $108.8M | $97.5M | — |
| Research and development | $13.7M | $12.0M | $13.8M | $16.7M | $68.9M |
| Operating expenses | $105.1M | $89.6M | $176.0M | $88.3M | $95.2M |
| Operating income | $11.5M | $16.2M | -$67.2M | $9.2M | -$87.9M |
| Pretax income | $14.4M | $23.2M | -$77.0M | $9.4M | -$87.9M |
| Income tax expense | $4.6M | $5.3M | $8.5M | $5.1M | — |
| Net income | $9.9M | $17.9M | -$85.5M | $4.3M | -$87.9M |
| Balance Sheet | |||||
| Cash and equivalents | $37.1M | $11.8M | $33.5M | $25.2M | $44.3M |
| Current assets | $102.4M | $64.8M | $57.2M | $49.7M | $51.5M |
| Total assets | $166.1M | $125.4M | $116.5M | $84.8M | $55.7M |
| Current liabilities | $18.3M | $19.5M | $20.0M | $12.2M | $14.2M |
| Total liabilities | $23.9M | $27.0M | $38.1M | $12.5M | $14.6M |
| Stockholders' equity | $106.0M | $63.3M | -$15.8M | $42.5M | $41.1M |
| Cash Flow Statement | |||||
| Cash from operations | $1.0M | -$3.6M | $25.9M | $10.7M | -$83.8M |
| Depreciation and amortization | $2.5M | $1.5M | $1.1M | $1.1M | $290,000 |
| Stock-based compensation | $7.2M | $831,000 | $7.3M | $13.4M | $3.4M |
| Capital expenditure | $1.2M | $2.3M | $8.5M | $5.0M | $839,000 |
| Free cash flow | -$180,000 | -$6.0M | $17.4M | $5.7M | -$84.6M |
| Dividends paid | — | — | — | $45.0M | — |
| Impairments | $0 | $0 | $0 | $0 | — |
Shares outstanding 97.0M · Free float 10.3%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.